Abstract
Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Current Pharmaceutical Design
Title:Stimuli-Responsive Nanoparticles for siRNA Delivery
Volume: 21 Issue: 29
Author(s): Josimar O. Eloy, Raquel Petrilli, Renata F. V. Lopez and Robert J. Lee
Affiliation:
Keywords: siRNA, nanoparticles, triggered release, environmental-responsive, drug delivery.
Abstract: Nanoparticles have been extensively employed to deliver many drugs, including siRNA, for the treatment of a variety of diseases, particularly cancer. Lately, there has been a great deal of effort to design nanoparticles with materials that are able to respond to intrinsic or extrinsic stimuli for “on demand” delivery of siRNA. These nanoparticles are able to trigger siRNA release upon different stimuli, such as a pH decrease, redox gradient, enzyme, light, magnetic field, temperature, ultrasound or electric current. Frequently, the stimuli cause the nanoparticles to undergo protonation, hydrolytic breakdown or phase transition for triggered release of siRNA, resulting in decreased side effects and better therapeutic outcome. While studies have demonstrated efficient in vitro and in vivo delivery, these “smart” nanoparticles have not yet reached the clinic. In this review, we address different classes of nanoparticles, such as polyplexes, lipoplexes, liposomes, polymeric micelles, polymeric, lipid and inorganic nanoparticles, that are able to respond to specific stimuli for siRNA triggered-release, emphasizing their application and discussing the latest advances.
Export Options
About this article
Cite this article as:
Eloy O. Josimar, Petrilli Raquel, Lopez F. V. Renata and Lee J. Robert, Stimuli-Responsive Nanoparticles for siRNA Delivery, Current Pharmaceutical Design 2015; 21 (29) . https://dx.doi.org/10.2174/1381612821666150901095349
DOI https://dx.doi.org/10.2174/1381612821666150901095349 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Co-Infections in Mother-to-Child Transmission of HIV
Current HIV Research Molecular Approaches to Cervical Cancer Therapy
Current Drug Discovery Technologies Structure-Activity Relationship Studies on Holy Basil (Ocimum sanctum L.) Based Flavonoid Orientin and its Analogue for Cytotoxic Activity in Liver Cancer Cell Line HepG2
Combinatorial Chemistry & High Throughput Screening Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Neonatal Germ Cell Tumors
Current Pediatric Reviews Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer
Current Genomics The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design
Current Pharmaceutical Design Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design NF-κB1 Intronic Region Polymorphisms as Risk Factor for Head and Neck Cancer in HPV-Infected Population from Pakistan
Current Molecular Medicine From TGF-β to Cancer Therapy
Current Drug Targets Nanotechnology in Dentistry: Drug Delivery Systems for the Control of Biofilm-Dependent Oral Diseases
Current Drug Delivery Inflammation, Microenvironment, and the Immune System in Cancer Progression
Current Pharmaceutical Design Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine Sigma-2 Receptor Ligands: Neurobiological Effects
Current Medicinal Chemistry